These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8367920)

  • 1. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.
    Denis LJ; Carnelro de Moura JL; Bono A; Sylvester R; Whelan P; Newling D; Depauw M
    Urology; 1993 Aug; 42(2):119-29; discussion 129-30. PubMed ID: 8367920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center.
    Denis LJ; Keuppens F; Smith PH; Whelan P; de Moura JL; Newling D; Bono A; Sylvester R
    Eur Urol; 1998; 33(2):144-51. PubMed ID: 9519355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of maximal androgen blockade in advanced prostate cancer.
    Denis L
    Prostate Suppl; 1994; 5():17-22. PubMed ID: 8172710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.
    Rosendahl I; Kiebert GM; Curran D; Cole BF; Weeks JC; Denis LJ; Hall RR
    Prostate; 1999 Feb; 38(2):100-9. PubMed ID: 9973095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.
    Keuppens F; Denis L; Smith P; Carvalho AP; Newling D; Bond A; Sylvester R; De Pauw M; Vermeylen K; Ongena P
    Cancer; 1990 Sep; 66(5 Suppl):1045-57. PubMed ID: 2144206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone therapy of prostatic bone metastases.
    Huben RP
    Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
    Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Chen Y; Kolvenbag GJ
    Cancer; 1996 Nov; 78(10):2164-9. PubMed ID: 8918410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
    Denis L; Smith PH; De Moura JL; Newling DW; Bono A; Keuppens F; Robinson M; Mahler C; Sylvester R; De Pauw M
    Eur Urol; 1990; 18 Suppl 3():34-40. PubMed ID: 2151274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
    Sylvester RJ; Denis L; de Voogt H
    Eur Urol; 1998; 33(2):134-43. PubMed ID: 9519354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
    Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Urology; 1995 May; 45(5):745-52. PubMed ID: 7538237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
    Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
    Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group.
    de Voogt HJ; Studer U; Schröder FH; Klijn JG; de Pauw M; Sylvester R
    Eur Urol; 1998; 33(2):152-8. PubMed ID: 9519356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
    J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
    Eisenberger MA; Blumenstein BA; Crawford ED; Miller G; McLeod DG; Loehrer PJ; Wilding G; Sears K; Culkin DJ; Thompson IM; Bueschen AJ; Lowe BA
    N Engl J Med; 1998 Oct; 339(15):1036-42. PubMed ID: 9761805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853).
    Denis L; Robinson M; Mahler C; Smith P; Keuppens F; De Moura JL; Bono A; Newling D; Sylvester R; De Pauw M
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):951-9. PubMed ID: 2149508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
    Labrie F; Dupont A; Cusan L; Giguere M; Bergeron N; Borsanyi JP; Lacourciere Y; Belanger A; Emond J; Monfette G
    J Steroid Biochem; 1988; 30(1-6):107-17. PubMed ID: 3290578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). European Organization for Research and Treatment of Cancer--Genitourinary Group.
    Keuppens F; Whelan P; Carneiro de Moura JL; Newling D; Bono A; Denis L; Robinson M; Mahler C; Sylvester R; De Pauw M
    Cancer; 1993 Dec; 72(12 Suppl):3863-9. PubMed ID: 8252505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
    Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Schellenger JJ; Kolvenbag GJ
    Urology; 1997 Sep; 50(3):330-6. PubMed ID: 9301693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.